Search

Your search keyword '"Inabnet, William B."' showing total 508 results
Start Over Author "Inabnet, William B."
508 results on '"Inabnet, William B."'

6. Contributors

Author

Abraham, Devaprabu, primary, Abraham, Nikita R., additional, Agarwal, Amit, additional, Ahadi, Mahsa S., additional, Alameer, Ehab, additional, Alobuia, Wilson, additional, Alon, Eran E., additional, Angkoon, Anuwong, additional, Al-Qurayshi, Zaid, additional, Angell, Trevor E., additional, Angelos, Peter, additional, Baek, Jung Hwan, additional, Baloch, Zubair W., additional, Barczyński, Marcin, additional, Bauer, Andrew J., additional, Bellantone, Rocco, additional, Berdelou, Amandine, additional, Bergenfeltz, Anders, additional, Bernet, Victor J., additional, Bible, Keith C., additional, Bilezikian, John Paul, additional, Bonilla-Velez, Juliana, additional, Boucai, Laura, additional, Brent, Gregory A., additional, Breuskin, Ingrid, additional, Brierley, James Duncan, additional, Brisebois, Simon, additional, Brooks, Jennifer, additional, Brumund, Kevin T., additional, Bura, Mijenko, additional, Alvarez, Jean Gabriel Bustamante, additional, Carneiro-Pla, Denise, additional, Cernea, Claudio R., additional, Chang, Rita Yuk-kwan, additional, Chen, Amy, additional, Chiang, Feng-Yu, additional, Chintakuntlawar, Ashish V., additional, Cho, Nancy L., additional, Chung, Woong Youn, additional, Cibas, Edmund S., additional, Dacey, Carolyn, additional, Davies, Louise, additional, De Crea, Carmela, additional, Delbridge, Leigh, additional, Diercks, Gillian, additional, Doherty, Gerard M., additional, Dralle, Henning, additional, Duh, Quan-Yang, additional, Dunlap, Quinn Alexander, additional, Durante, Cosmio, additional, Eltelety, Ahmad Mohamed, additional, Evans, Douglas B., additional, Fadda, Guido, additional, Faquin, William C., additional, Felger, Erin, additional, Ferris, Robert L., additional, Filetti, Sebastiano, additional, Freeman, Jeremy L., additional, Fundakowski, Christopher, additional, Ganly, Ian, additional, Gigliotti, Benjamin Joseph, additional, Gill, Anthony J., additional, Giordano, Thomas J., additional, Giuliani, Meredith E., additional, Gooi, Zhen, additional, Gopal, Raj K., additional, Guerlain, Joanne, additional, Hadoux, Julien, additional, Hales, Nathan, additional, Hartl, Dana, additional, Haugen, Bryan R., additional, Haymart, Megan R., additional, Inabnet, William B., additional, Irish, Jonathan, additional, Iwata, Ayaka, additional, Kamani, Dipti, additional, Kandil, Emad, additional, Kaplan, Edwin L., additional, Kazahaya, Ken, additional, Kebebew, Electron, additional, Kim, Matthew I., additional, Kovatch, Kevin J., additional, Lang, Brian H.H., additional, Leboulleux, Sophie, additional, Leung, Angela M., additional, Levine, Robert A., additional, Liddy, Whitney, additional, LiVolsi, Virginia A., additional, Lombardi, Celestino Pio, additional, Lubitz, Carrie C., additional, Machens, Andreas, additional, Maghami, Ellie, additional, Mandel, Susan J., additional, Maniakas, Anastasios, additional, Mathisen, Douglas J., additional, Mathur, Aarti, additional, Merati, Albert, additional, Milas, Mira, additional, Miyauchi, Akira, additional, Monteiro, Eric, additional, Netterville, James L., additional, Nikiforov, Yuri E., additional, Orloff, Lisa A., additional, Pandian, T.K., additional, Parangi, Sareh, additional, Parikh, Sanjay, additional, Park, Auh Whan, additional, Pearce, Elizabeth N., additional, Pellitteri, Phillip K., additional, Pennestrì, Francesco, additional, Pradhan, Roma, additional, Prichard, Ruth, additional, Raffaelli, Marco, additional, Randolph, Gregory W., additional, Rastatter, Jeff, additional, Reid, Lisa M., additional, Richer, Sara L., additional, Richmon, Jeremy D., additional, Ringel, Matthew D., additional, Roman, Benjamin R., additional, Romanchishen, Anatoly F., additional, Ross, Douglas S., additional, Russell, Jonathon O., additional, Russell, Marika D., additional, Ryder, Mabel, additional, Sabra, Mona M., additional, Sachdeva, Uma M., additional, Sadow, Peter M., additional, Scharpf, Joseph, additional, Schlumberger, Martin, additional, Schneider, Rick, additional, Scott-Coombes, David, additional, Sewell, Andrew B., additional, Shah, Jatin, additional, Shah, Manisha H., additional, Shindo, Maisie, additional, Shonka, David, additional, Silverberg, Shonni Joy, additional, Sims, John Randall, additional, Sinclair, Catherine F., additional, Singer, Michael C., additional, Siperstein, Allan E., additional, Sipos, Jennifer A., additional, Slough, Cristian Martin, additional, Sosa, Julie A., additional, Soylu, Selen, additional, Stack, Brendan C., additional, Stathatos, Nikolaos, additional, Stechman, Michael James, additional, Stephen, Antonia E., additional, Steward, David L., additional, Suh, Hyun, additional, Sywak, Mark, additional, Tang, Alice, additional, Terris, David J., additional, Thompson, Geoffrey Bruce, additional, Tolley, Neil, additional, Tominaga, Yoshihiro, additional, Triponez, Frédéric, additional, Tsang, Richard W., additional, Tuttle, R. Michael, additional, Urken, Mark L., additional, Vabalayte, Kristina V., additional, Vahabzadeh-Hagh, Andrew M., additional, Volpi, Erivelto Martinho, additional, Wang, Tracy S., additional, Wu, Che-Wei, additional, Wirth, Lori J., additional, Witterick, Ian, additional, Wong, Richard J., additional, Woodson, Gayle E., additional, Wright, Cameron D., additional, Zafereo, Mark E., additional, and Zubiaur, Fermin M., additional

Published
2021
Full Text
View/download PDF

9. List of Contributors

Author

Asare, Elliot A., primary, Bai, Harrison X., additional, Bancos, Irina, additional, Bauer, Andrew J., additional, Carmela, De Crea, additional, Chen, Yufei, additional, Delivanis, Danae, additional, Dralle, Henning, additional, Duh, Quan-Yang, additional, Fahey, Thomas J., additional, Fernandez Ranvier, Gustavo G., additional, Finnerty, Brendan M., additional, Fisher, Sarah B., additional, Francesco, Pennestrì, additional, Habra, Mouhammed Amir, additional, Hallman, Joan, additional, Halsey, Jordan N., additional, Hamidi, Oksana, additional, Inabnet, William B., additional, Ito, Yasuhiro, additional, Kebebew, Electron, additional, Krasnova, Svetlana L., additional, Kruijff, Schelto, additional, Laird, Amanda M., additional, Lee, James A., additional, Libutti, Steven K., additional, Lou, Irene, additional, Machens, Andreas, additional, Maggio, William W., additional, Marcadis, Andrea R., additional, Raffaelli, Marco, additional, Mazeh, Haggi, additional, McCartney-Anderson, Maureen, additional, Mekel, Michal, additional, Meknat, Aryan, additional, Miyauchi, Akira, additional, Nobecourt, Priscilla, additional, Patel, Tushar R., additional, Pearlstein, Sarah S., additional, Perrier, Nancy D., additional, Pio, Lombardi Celestino, additional, Rocco, Bellantone, additional, Schmid, Kurt Werner, additional, Shah, Meera, additional, Shaha, Ashok R., additional, Shargorodsky, Josef, additional, Sharma, Anu, additional, Shifrin, Alexander L., additional, Silva-Figueroa, Angelica M., additional, Sinclair, Tiffany J., additional, Stratakis, Constantine A., additional, Suzuki, Mari, additional, Trerotola, Scott O., additional, van der Plas, Willemijn Y., additional, Vogt, Liffert, additional, and Yalon, Tal, additional

Published
2020
Full Text
View/download PDF

13. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA)

Author

Ho, Alan L., Dedecjus, Marek, Wirth, Lori J., Tuttle, R. Michael, Inabnet, William B., Tennvall, Jan, Vaisman, Fernanda, Bastholt, Lars, Gianoukakis, Andrew G., Rodien, Patrice, Paschke, Ralf, Elisei, Rossella, Viola, David, So, Karen, Carroll, Danielle, Hovey, Tina, Thakre, Bhavana, and Fagin, James A.

Subjects
Iodine Radioisotopes, Cancer Research, Clinical Trials, Phase III as Topic, Oncology, Humans, Benzimidazoles, ORIGINAL REPORTS, Thyroid Neoplasms, Mitogen-Activated Protein Kinases, Protein Kinase Inhibitors
Abstract

PURPOSE Selumetinib can increase radioactive iodine (RAI) avidity in RAI-refractory tumors. We investigated whether selumetinib plus adjuvant RAI improves complete remission (CR) rates in patients with differentiated thyroid cancer (DTC) at high risk of primary treatment failure versus RAI alone. METHODS ASTRA (ClinicalTrials.gov identifier: NCT01843062 ) is an international, phase III, randomized, placebo-controlled, double-blind trial. Patients with DTC at high risk of primary treatment failure (primary tumor > 4 cm; gross extrathyroidal extension outside the thyroid gland [T4 disease]; or N1a/N1b disease with ≥ 1 metastatic lymph node(s) ≥ 1 cm or ≥ 5 lymph nodes [any size]) were randomly assigned 2:1 to selumetinib 75 mg orally twice daily or placebo for approximately 5 weeks (no stratification). On treatment days 29-31, recombinant human thyroid-stimulating hormone (0.9 mg)–stimulated RAI (131I; 100 mCi/3.7 GBq) was administered, followed by 5 days of selumetinib/placebo. The primary end point (CR rate 18 months after RAI) was assessed in the intention-to-treat population. RESULTS Four hundred patients were enrolled (August 27, 2013-March 23, 2016) and 233 randomly assigned (selumetinib, n = 155 [67%]; placebo, n = 78 [33%]). No statistically significant difference in CR rate 18 months after RAI was observed (selumetinib n = 62 [40%]; placebo n = 30 [38%]; odds ratio 1.07 [95% CI, 0.61 to 1.87]; P = .8205). Treatment-related grade ≥ 3 adverse events were reported in 25/154 patients (16%) with selumetinib and none with placebo. The most common adverse event with selumetinib was dermatitis acneiform (n = 11 [7%]). No treatment-related deaths were reported. CONCLUSION Postoperative pathologic risk stratification identified patients with DTC at high risk of primary treatment failure, although the addition of selumetinib to adjuvant RAI failed to improve the CR rate for these patients. Future strategies should focus on tumor genotype–tailored drug selection and maintaining drug dosing to optimize RAI efficacy.

Published
2022

17. Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial

Author

Ikramuddin, Sayeed, Billington, Charles J, Lee, Wei-Jei, Bantle, John P, Thomas, Avis J, Connett, John E, Leslie, Daniel B, Inabnet, William B, III, Jeffery, Robert W, Chong, Keong, Chuang, Lee-Ming, Sarr, Michael G, Jensen, Michael D, Vella, Adrian, Ahmed, Leaque, Belani, Kumar, Schone, Joyce L, Olofson, Amy E, Bainbridge, Heather A, Laqua, Patricia S, Wang, Qi, and Korner, Judith

Published
2015
Full Text
View/download PDF

22. Lifestyle Intervention and Medical Management With vs Without Roux-en-Y Gastric Bypass and Control of Hemoglobin A1c, LDL Cholesterol, and Systolic Blood Pressure at 5 Years in the Diabetes Surgery Study

Author

Ikramuddin, Sayeed, Korner, Judith, Lee, Wei-Jei, Thomas, Avis J., Connett, John E., Bantle, John P., Leslie, Daniel B., Wang, Qi, Inabnet, William B., III, Jeffery, Robert W., Chong, Keong, Chuang, Lee-Ming, Jensen, Michael D., Vella, Adrian, Ahmed, Leaque, Belani, Kumar, and Billington, Charles J.

Published
2018
Full Text
View/download PDF

25. Adrenal Insufficiency

Author

Inabnet, William B., III, Saclarides, Theodore J., editor, Millikan, Keith W., editor, and Godellas, Constantine V., editor

Published
2003
Full Text
View/download PDF

33. Opioid-Free Thyroid and Parathyroid Operations: Are Patients Satisfied With Pain Control?

Author

Leader, Preston W., Oyler, Douglas R, Carter, Tonya M, Damron, Donna S., Lee, Cortney Y., Sloan, David A, Inabnet, William B, and Randle, Reese W.

Abstract

Background The aim of this study was to evaluate pain control and patient satisfaction using an opioid-free analgesic regimen following thyroid and parathyroid operations.Methods Surveys were distributed to all postoperative patients following total thyroidectomy, thyroid lobectomy, and parathyroidectomy between January and April 2020. After surgery, patients were discharged without opioids except in rare cases based on patient needs and surgeon judgment. We measured patient-reported Numeric Rating Scale (NRS) pain scores and satisfaction categorically as either satisfied or dissatisfied.Results We received 90 of 198 surveys distributed, for a 45.5% response rate. After excluding neck dissections (n = 6) and preoperative opioid use (n = 4), the final cohort included 80 patients after total thyroidectomy (26.3%), thyroid lobectomy (41.3%), and parathyroidectomy (32.5%).The majority reported satisfaction with pain control (87.5%) and the entire surgical experience (95%). A similar proportion of patients reported satisfaction with pain control after total thyroidectomy (90.9%), thyroid lobectomy (90.5%), and parathyroidectomy (80.8%), indicating the procedure did not significantly impact satisfaction with pain control (P= .47). Patients who reported dissatisfaction with pain control were more likely to receive opioid prescriptions (30% vs 2.9%, P< .01), but the majority still reported satisfaction with their entire operative experience (70%).Discussion Even with an opioid-free postoperative pain regimen, most patients report satisfaction with pain control after thyroid and parathyroid operations, and those who were dissatisfied with their pain control generally reported satisfaction with their overall surgical experience. Therefore, an opioid-free postoperative pain control regimen is well tolerated and unlikely to decrease overall patient satisfaction.

Published
2023
Full Text
View/download PDF

41. Feasibility of the TOETVA as an Ambulatory Procedure

Author

Lieberman Benjamin, Meknat Aryan, Alawwa Ghayth, Guevara Daniela, Inabnet William B, and Fernández-Ranvier Gustavo G

Subjects
medicine.medical_specialty, business.industry, Emergency medicine, Ambulatory, medicine, business
Published
2020

Catalog

Books, media, physical & digital resources
See catalog results